Temsirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is a new targeted therapy used in advanced renal cell carcinoma and mantle cell lymphoma and is currently tested in several other human tumors. It induces several cutaneous and mucosal side effects, including painful, dose-limiting stomatitis. We report the unusual case of a 77-year-old man who developed severe mucosal, scrotal and perianal cutaneous aphthous-like ulcerations, 6 weeks after introduction of temsirolimus therapy for advanced-stage renal cell carcinoma. Other causes of aphthous-like ulcerations were ruled out. Topical corticosteroids remained ineffective. It led to the interruption of the treatment. Introduction of colchicine resulted in a dramatic improvement within 1 month. Reintroduction of temsirolimus with concomitant colchicine therapy was followed by a delayed recurrence of the lesions. We provide here a review of the potential cutaneous and mucosal side effects of mTOR inhibitors.

Keywords:
Temsirolimus, Mammalian target of rapamycin, Renal cell carcinoma
1.
Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–2281.
2.
Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
3.
Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66:5549–5554.
4.
Hidalgo M, Buckner JC, Erlichman C, et al: A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006;12:5755–5763.
5.
Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1387–1392.
6.
Campistol JM, de Fijter JW, Flechner SM, et al: mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010;24:149–156.
7.
Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
8.
Katz J, Langevitz P, Shemer J, et al: Prevention of recurrent aphthous stomatitis with colchicine: an open trial. J Am Acad Dermatol 1994;31:459–461.
9.
Fontes V, Machet L, Huttenberger B, et al: Recurrent aphthous stomatitis: treatment with colchicine: an open trial of 54 cases. Ann Dermatol Venereol 2002;129:1365–1369.
10.
Scully C: Clinical practice: aphthous ulceration. N Engl J Med 2006;355:165–172.
11.
Choi YL, Kim JA, Jang KT, et al: Characteristics of cutaneous cytomegalovirus infection in non-acquired immune deficiency syndrome, immunocompromised patients. Br J Dermatol 2006;155:977–982.
12.
Abraham RT, Gibbons JJ: The mammalian target of rapamycin signalling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109–3114.
13.
Figlin RA: Mechanisms of disease: Survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nat Clin Pract Oncol 2008;5:601–609.
14.
Javier AF, Bata-Csorgo Z, Ellis CN, et al: Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Invest 1997;99:2094–2099.
15.
Duncan JI: Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. J Invest Dermatol 1994;102:84–88.
16.
Reitamo S, Spuls PI, Sassolas B, et al, for the Sirolimus European Psoriasis Study Group: Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001;145:438–445.
17.
Schäffer M, Schier R, Napirei M, Michalski S, Traska T, Viebahn R: Sirolimus impairs wound healing. Langenbecks Arch Surg 2007;392:297–303.
18.
Dormond O, Contreras AG, Meijer E, et al: CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J Immunol 2008;181:8088–8095.
19.
Mahe E, Morelon E, Lechaton S, et al: Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005;79:476–482.
20.
Van Gelder T, ter Meulen C, Hené R, Weimar W, Hoitsma A: Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75:788–791.
21.
Warino L, Libecco J: Cutaneous effects of sirolimus in renal transplant recipients. J Drugs Dermatol 2006;5:273–274.
22.
Fasolo A, Sessa C: mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008;17:1717–1734.
23.
Vignot S, Faivre S, Aquirre D, et al: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525–527.
24.
Chuang P, Langone AJ: Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 2007;7:714–717.
25.
Sullivan TP, King LE Jr, Boyd AS: Colchicine in dermatology. J Am Acad Dermatol 1998;39:993–999.
26.
Epailly E, Lorho R: Side effects of proliferation signal inhibitors and their management. Gastroenterol Clin Biol 2009;33:268–274.
27.
Kahan BD, for the Rapamune US Study Group: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000;356:194–202.
28.
Dereure O: Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies. Expert Opin Drug Saf 2003;2:467–473.
29.
Motzer RJ, Escudier B, Oudard S, et al, RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–456.
30.
Ravaud A: Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011;16(suppl 2):32–44.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.